Merit Medical Systems Inc
$ 70.54
-0.04%
14 Apr - close price
- Market Cap 4,194,111,000 USD
- Current Price $ 70.54
- High / Low $ 71.58 / 70.12
- Stock P/E 33.13
- Book Value 26.66
- EPS 2.13
- Next Earning Report 2026-04-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.09 %
- 52 Week High 100.19
- 52 Week Low 66.34
About
Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, intensive care, and endoscopy. The company is headquartered in South Jordan, Utah.
Analyst Target Price
$101.18
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-24 | 2025-10-30 | 2025-07-30 | 2025-04-28 | 2025-02-26 | 2024-10-30 | 2024-08-01 | 2024-04-30 | 2024-02-28 | 2023-10-26 | 2023-07-25 | 2023-04-26 |
| Reported EPS | 1.04 | 0.92 | 1.01 | 0.86 | 0.93 | 0.86 | 0.92 | 0.77 | 0.81 | 0.75 | 0.81 | 0.64 |
| Estimated EPS | 0.9498 | 0.83 | 0.8475 | 0.7493 | 0.83 | 0.8 | 0.87 | 0.71 | 0.77 | 0.65 | 0.75 | 0.55 |
| Surprise | 0.0902 | 0.09 | 0.1625 | 0.1107 | 0.1 | 0.06 | 0.05 | 0.06 | 0.04 | 0.1 | 0.06 | 0.09 |
| Surprise Percentage | 9.4967% | 10.8434% | 19.174% | 14.7738% | 12.0482% | 7.5% | 5.7471% | 8.4507% | 5.1948% | 15.3846% | 8% | 16.3636% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.73 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MMSI
2026-04-13 20:10:19
Merit Medical Systems, Inc. has filed an 8-K report to provide updated historical revenue breakdowns aligned with its new foundational and therapeutic product categories. The report includes financial data for the years 2022-2025 and quarterly results from Q1 2024 through Q4 2025, detailing revenues by categories like Access, OEM, Cardiac Therapies, and Oncology. This information is supplemental, not a restatement of previous financial statements, and is furnished under Regulation FD.
2026-04-11 10:40:00
This article analyzes Merit Medical Systems Inc. (NASDAQ: MMSI) using AI-generated real-time signals, noting stable neutral readings in shorter horizons but an elevated downside risk in the long term. It presents three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide investors. The analysis emphasizes detailed support and resistance levels across different time horizons for MMSI.
2026-04-11 05:38:45
Merit Medical Systems recently acquired View Point Medical and expanded its distribution agreement with Medtronic, moves aimed at enhancing its presence in interventional medical devices and minimally invasive therapies. While the acquisition may initially dilute earnings due to integration costs, it's expected to expand Merit’s product portfolio and market reach through Medtronic's global distribution network. Investors are encouraged to monitor the integration process, revenue contributions from the Medtronic deal, and the impact on profit margins.
2026-04-09 18:39:27
Baker McKenzie advised Merit Medical Systems, Inc. on its acquisition of View Point Medical, Inc. for approximately USD 140 million. The deal expands Merit's therapeutic oncology portfolio by adding View Point's OneMark® Detection Imaging System and OneMark® Tissue Markers, which are FDA-cleared technologies that complement Merit’s existing SCOUT® platform for lesion localization during biopsies.
2026-04-07 16:40:31
Canaccord has reduced its price target for Merit Medical Systems (NASDAQ:MMSI) from $99 to $90, while maintaining a Buy rating. This adjustment follows Merit Medical's recent $140 million acquisition, which is expected to dilute non-GAAP EPS in 2026 before becoming accretive by 2027. The article also notes mixed analyst sentiment, with BTIG reiterating a Buy rating and Wells Fargo downgrading the stock due to uncertainty surrounding future guidance.
2026-04-07 11:39:46
Canaccord has lowered its price target for Merit Medical Systems (NASDAQ:MMSI) to $90 from $99, while maintaining a Buy rating, due to the impact of a recent $140 million acquisition. Despite the price target cut and an expected short-term EPS dilution, the acquisition is projected to contribute significantly to revenue and become accretive to non-GAAP EPS by 2027. This news comes amidst mixed analyst views, with BTIG reiterating a Buy rating, but Wells Fargo downgrading the stock to Equal Weight due to concerns over future guidance.
